Herpes Simplex Virus 1 (HSV-1) for Glioblastoma Multiforme Therapy
Author:
Hadjipanayis Costas G.
Reference181 articles.
1. Advani, S. J., Mezhir, J. J., Roizman, B., and Weichselbaum, R. R. (2006). ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66, 637–646. 2. Advani, S. J., Sibley, G. S., Song, P. Y., Hallahan, D. E., Kataoka, Y., Roizman, B., and Weichselbaum, R. R. (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5, 160–165. 3. Aghi, M., Rabkin, S., and Martuza, R. L. (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98, 38–50. 4. Andreansky, S., He, B., van Cott, J., McGhee, J., Markert, J. M., Gillespie, G. Y., Roizman, B., and Whitley, R. J. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5, 121–130. 5. Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., and Harvey-White, J. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164, 2–14.
|
|